Somewhere along the way these two compounds stopped being discussed separately. Search either one and you get the pair, usually with a nickname borrowed from a comic book character and a promise about recovery that nobody bothers to source. They have become a package deal in the popular imagination.
The pairing is not arbitrary. There is a mechanistic argument for it, and it is a reasonably good one. It is also worth knowing exactly how much of that argument comes from published research and how much comes from the internet, because the answer is not what the marketing suggests. This is a look at what BPC-157 and TB-500 each are, what the studies on them actually cover, and where the evidence stops.
What BPC-157 and TB-500 are
BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids taken from a larger protein found in human gastric juice, which is a slightly unglamorous origin story for something marketed as elite recovery science. Croatian researchers first characterized it in the 1990s, and the same group has produced a large share of the literature since.
TB-500 is a different kind of thing entirely, and this is the first place most articles go wrong. It is a synthetic seven-amino-acid fragment corresponding to the actin-binding domain of thymosin beta-4, a naturally occurring 43-amino-acid protein. TB-500 and thymosin beta-4 are routinely treated as the same molecule. They are not. One is a short fragment of the other, and the clinical research that gets cited for TB-500 was almost always conducted on the full protein.
That distinction matters more than it sounds. Thymosin beta-4 has been through actual human trials, run by RegeneRx for dry eye disease, pressure ulcers and epidermolysis bullosa, with mixed results across the programs. TB-500 has not. When someone points at “the clinical trials on TB-500,” they are almost certainly pointing at trials of a different, longer molecule.
Why researchers pair BPC-157 and TB-500
The rationale is about scope, and it is genuinely elegant on paper.
BPC-157 is studied mostly as a local actor. In animal models it appears to work at the site of injury, interacting with the nitric oxide system and upregulating VEGFR2, a receptor central to angiogenesis, the growth of new blood vessels. New vessels mean blood supply reaching tissue that has lost it, which is the rate-limiting step in healing structures like tendon and ligament that are poorly vascularized to begin with.
TB-500 is studied as a systemic actor. Thymosin beta-4’s main documented job is sequestering G-actin, the monomer form of the protein that cells use to build their internal scaffolding. Regulating that pool governs how readily cells can reorganize and migrate. Migration is how repair cells get to damaged tissue in the first place.
So the theory: one compound helps cells reach the site, the other helps build the blood supply once they arrive. Different mechanisms, complementary jobs, no obvious overlap. As reasoning goes it is clean, and it explains why the combination caught on the way it did.
Hold onto the word “theory.” It comes back later.
What the BPC-157 research actually covers
The BPC-157 literature is substantial and almost entirely preclinical.
Rodent studies have examined Achilles tendon transection, medial collateral ligament injury, muscle crush injury, and various models of gut damage including induced colitis and NSAID-related lesions. Reported outcomes include faster tendon healing, improved biomechanical strength in repaired tissue, and protective effects on intestinal lining.
The gut work is the most mechanistically coherent part of the file, which makes sense given the compound was isolated from gastric juice. Some of the most cited papers concern intestinal barrier function rather than the tendon results the compound is sold on.
Now the limits, which are large. There are no published randomized controlled trials in humans. Not few. None. A disproportionate share of the animal work comes from a small number of affiliated research groups, which is a known weakness in any literature because independent replication is what separates a real effect from a lab artifact. And oral bioavailability, which is the basis for a whole category of capsule products, rests on rodent data that has not been confirmed in people.
What the TB-500 research actually covers
Most of the useful evidence here belongs to thymosin beta-4 rather than to TB-500 itself.
Thymosin beta-4 has been studied in models of corneal wound healing, cardiac tissue after ischemic injury, and dermal wound repair. It reached human trials in several indications. Results were uneven: some endpoints moved, others did not, and no program produced an approval.
The research on the short fragment specifically is far thinner. The working assumption is that the actin-binding domain carries most of the activity, which is a reasonable hypothesis and not a demonstrated fact. A fragment can behave differently from its parent protein in distribution, stability, and how long it survives in circulation.
What is well documented is TB-500’s popularity in veterinary and equine settings, where it has been used for tendon and ligament injury in racehorses for years. That is a real body of practical experience. It is also not the same as controlled human evidence, and it is a large part of why the compound has the reputation it does.
BPC-157 and TB-500 compared side by side
| BPC-157 | TB-500 | |
|---|---|---|
| Structure | 15 amino acids, from a gastric protein | 7 amino acids, fragment of thymosin beta-4 |
| Primary studied mechanism | Angiogenesis via VEGFR2, nitric oxide pathway | G-actin sequestration, cell migration |
| Scope of action in models | Largely local to the injury site | Systemic |
| Best documented areas | Tendon, ligament, gastrointestinal tissue | Cornea, cardiac tissue, dermal wounds (as thymosin beta-4) |
| Human trial data | None published | None on the fragment; parent protein trialed with mixed results |
| Anti-doping status | Prohibited by WADA | Prohibited by WADA |
What no study has tested: the BPC-157 and TB-500 combination
Here is the thing the entire category is built on, and it is worth saying without hedging.
No published study has tested BPC-157 and TB-500 together. Not in humans, and as far as the available literature shows, not in animals either. Every claim about synergy between these two compounds is an inference drawn from their separate mechanisms. It is not a finding.
Inference from mechanism is a normal and useful thing to do in research. It generates hypotheses. It is how you decide which combination is worth the cost of testing. What it is not is evidence, and pharmacology is full of pairings that looked complementary on a whiteboard and did nothing measurable, or occasionally something unwanted, once anyone checked.
So the honest position on the pair is that the reasoning is sound and untested. Both of those words carry equal weight. Anyone presenting the combination as an established protocol is describing a hypothesis in the voice of a conclusion, and once you notice that pattern in this space you start seeing it everywhere.
BPC-157 and TB-500 research in women: what is missing
There is a gap in this literature that almost nobody writing about recovery peptides mentions, and it is not subtle once you look for it.
Preclinical research has a long-documented habit of running on male animals. The reasons given were practical rather than malicious, mostly the argument that estrous cycling adds variability, and the NIH began requiring sex as a biological variable in its funded research in 2016 partly to correct it. The BPC-157 and thymosin beta-4 work largely predates that requirement, and a great deal of it used male rodents by default.
Tissue repair is not sex-neutral. Estrogen influences collagen synthesis and turnover, tendon stiffness varies across the menstrual cycle, and injury rates for certain soft tissue structures differ measurably between men and women. Anterior cruciate ligament injury is the most studied example and not the only one. Those are the exact tissues this category is marketed against.
None of that means the compounds behave differently in women. It means nobody checked. Which is a real answer, and a more useful one than the confident paragraph most sites offer on the subject.
The regulatory picture for BPC-157 and TB-500
This part changed recently enough that a lot of published content is out of date.
In 2023 the FDA placed BPC-157 in Category 2 of its review of bulk drug substances for compounding under section 503A, the category for substances that raise significant safety concerns or lack sufficient characterization. In practical terms that made it much harder for compounding pharmacies in the US to supply it, which is why availability shifted toward research suppliers.
Both compounds appear on the World Anti-Doping Agency prohibited list. BPC-157 was added in 2022 under S0, the class covering substances with no current approval for human therapeutic use. TB-500 has been prohibited for longer. For anyone subject to testing this is not a gray area.
Neither compound is approved for human use in any jurisdiction. Both are sold as research materials, and that framing is a legal description of what they are rather than a formality attached to the end of a product page.
Where to buy BPC-157 and TB-500, and what to check first
Purity is the variable that decides whether any of the research above is even relevant to the vial in front of you, and it is invisible without documentation.
What to check: a third-party lab certificate, not an in-house one. A batch number on the certificate that matches the number on the vial. Purity determined by HPLC. Identity confirmed by mass spectrometry, because purity alone tells you the contents are consistent without telling you what they are.
Healio publishes every batch certificate openly at the research page, before purchase rather than on request afterward. BPC-157 and TB-500 are stocked individually and together in the Restore Stack, alongside the rest of the peptides for healing collection. Both arrive lyophilized, and the reconstitution guide covers solvent choice and stability if you have not handled powder vials before.
BPC-157 and TB-500: frequently asked questions
What do BPC-157 and TB-500 do?
In animal models, BPC-157 promotes new blood vessel growth at injury sites through VEGFR2 signaling and shows protective effects on gastrointestinal tissue. TB-500 corresponds to the actin-binding region of thymosin beta-4 and is studied for its role in cell migration. Neither has published human trial data.
How do BPC-157 and TB-500 work together?
The proposed answer is that BPC-157 acts locally on blood supply while TB-500 acts systemically on cell migration. That explanation comes from combining what is known about each compound separately. No study has tested them together, so the synergy is a hypothesis rather than a documented result.
Can BPC-157 and TB-500 be mixed in one vial?
They are sometimes supplied as a pre-blended lyophilized powder, in which case a single reconstitution is straightforward. Combining two separately lyophilized compounds into one vial is a different matter, because it makes the concentration of each harder to verify and complicates any later analysis. Keeping them separate is the cleaner lab practice.
Where can you buy BPC-157 and TB-500?
Both are sold by research chemical suppliers rather than pharmacies, since the FDA’s 2023 compounding decision restricted BPC-157 availability through that route. The thing that separates suppliers is documentation. Healio stocks both compounds and publishes third-party certificates of analysis for every batch.
Is BPC-157 banned?
It is prohibited in sport. WADA added BPC-157 to its prohibited list in 2022 under class S0. It is not an approved drug in any jurisdiction, and the FDA’s 2023 Category 2 classification restricted its use in pharmacy compounding. It remains legal to sell and purchase as a research material.
Related reading
- Peptides for Recovery: the wider tissue repair category and what the evidence supports
- How to Reconstitute Peptides: solvent choice, the concentration math, and stability
- Best Peptides for Women: the full picture, sorted by research goal
- KPV Peptide Benefits: the anti-inflammatory side of the recovery category
Research use only. Every compound referenced on this page is supplied strictly for laboratory research. Nothing here is dosing guidance, and you will not find administration instructions anywhere on this site. These materials are not for human consumption, have not been evaluated by the FDA, and nothing here is medical advice. Consult a qualified healthcare professional for questions about your own health.